Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Consensus Guidelines: Pathology and molecular biomarkers for non-small-cell lung cancer

Published in 2014 - Ann Oncol (2014) 25 (9): 1681-1690. doi: 10.1093/annonc/mdu145
Authors: K.M. Kerr, L. Bubendorf, M.J. Edelman, A. Marchetti, T. Mok, S. Novello, K. O'Byrne, R. Stahel, S. Peters, E. Felip

This report from the 2nd ESMO Consensus Conference on Lung Cancer complements existing guidelines and provides recommendations by international experts on guidance on tissue handling, small biopsy/cytology diagnostic setting, testing for EGFR somatic mutations & ALK rearrangements, when to consider KRAS, BRAF, HER2, ROS1 fusion, RET fusion testing, if there is a role for ERCC1, RRM1, TS testing, the role of emerging technologies, why laboratories should participate in quality assurance programmes, and reporting data from pathological, molecular & other biomarker testing.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings